C. Winter

发表

An Unbiased Oncology Compound Screen to Identify Novel Combination Strategies

Yair Benita, J. O'neil, I. Feldman, 2016, Molecular Cancer Therapeutics.

Glutaminase is essential for the growth of triple-negative breast cancer cells with a deregulated glutamine metabolism pathway and its suppression synergizes with mTOR inhibition

D. Wiederschain, C. Winter, J. Pollard, 2017, PloS one.

FBW7 mutations in leukemic cells mediate NOTCH pathway activation and resistance to γ-secretase inhibitors

Rob Pieters, Christopher Winter, Giulio Draetta, 2007, The Journal of experimental medicine.

Anti–miR-21 Suppresses Hepatocellular Carcinoma Growth via Broad Transcriptional Network Deregulation

R. Baffa, A. Pavlícek, Sung‐Min Ahn, 2015, Molecular Cancer Research.

Combination of the mTOR Inhibitor Ridaforolimus and the Anti-IGF1R Monoclonal Antibody Dalotuzumab: Preclinical Characterization and Phase I Clinical Trial

J. Baselga, J. Bendell, I. Braña, 2014, Clinical Cancer Research.

Inhibition of NOTCH signaling by gamma secretase inhibitor engages the RB pathway and elicits cell cycle exit in T-cell acute lymphoblastic leukemia cells.

Xudong Dai, Theresa Zhang, Jing Yuan, 2009, Cancer research.

Oncogenic dependency on β-catenin in liver cancer cell lines correlates with pathway activation

D. Wiederschain, C. Winter, L. Schweizer, 2017, Oncotarget.

Dependence on the Pyrimidine Biosynthetic Enzyme DHODH Is a Synthetic Lethal Vulnerability in Mutant KRAS-Driven Cancers.

Q. Gao, I. Cornella-Taracido, C. García-echeverría, 2018, Cell chemical biology.

Tumor-derived JAGGED1 promotes osteolytic bone metastasis of breast cancer by engaging notch signaling in bone cells.

Yibin Kang, C. Winter, N. Sethi, 2011, Cancer cell.

Downregulation of Notch pathway by a gamma-secretase inhibitor attenuates AKT/mammalian target of rapamycin signaling and glucose uptake in an ERBB2 transgenic breast cancer model.

T. Yeatman, D. Coppola, P. Majumder, 2010, Cancer research.

Pan-TGFβ inhibition by SAR439459 relieves immunosuppression and improves antitumor efficacy of PD-1 blockade

A. Protopopov, D. Wiederschain, C. Winter, 2020, Oncoimmunology.

Interconnecting molecular pathways in the pathogenesis and drug sensitivity of T-cell acute lymphoblastic leukemia.

Richard S Larson, Jennifer O'Neil, Donna S Neuberg, 2010, Blood.

Experimental Therapeutics, Molecular Targets, and Chemical Biology De novo Discovery of a γ-Secretase Inhibitor Response Signature Using a Novel In vivo Breast Tumor Model

P. Majumder, J. Watters, C. Winter, 2009 .

Evidence of mTOR Activation by an AKT-Independent Mechanism Provides Support for the Combined Treatment of PTEN-Deficient Prostate Tumors with mTOR and AKT Inhibitors.

C. Paweletz, P. Majumder, K. Kunii, 2012, Translational oncology.

First Selective Small Molecule Inhibitor of FGFR4 for the Treatment of Hepatocellular Carcinomas with an Activated FGFR4 Signaling Pathway.

Nicolas Stransky, C. Lengauer, C. Winter, 2015, Cancer discovery.

Combination of themTOR Inhibitor Ridaforolimus and the Anti-IGF1R Monoclonal Antibody Dalotuzumab: Preclinical Characterization and Phase I Clinical Trial

S. Cosimo, J. Bendell, B. Haines, 2014 .

Abstract 943: SAR439859, an orally bioavailable selective estrogen receptor degrader (SERD) that demonstrates robust antitumor efficacy and limited cross-resistance in ER+ breast cancer

C. García-echeverría, C. Winter, L. Debussche, 2018, Endocrinology.

Identification of the endosomal sorting complex required for transport-I (ESCRT-I) as an important modulator of anti-miR uptake by cancer cells

Madelyn Light, Q. Gao, D. Wiederschain, 2014, Nucleic acids research.

Experimental Therapeutics, Molecular Targets, and Chemical Biology De novo Discovery of a γ-Secretase Inhibitor Response Signature Using a Novel In vivo Breast Tumor Model

P. Majumder, J. Watters, C. Winter, 2009 .

Abstract 5550: Translational biomarkers for SAR439459, an anti-TGFβ antibody for cancer immunotherapy

Tun Tun Lin, P. Mankoo, D. Wiederschain, 2018, Clinical Research (Excluding Clinical Trials).

Inhibition of NOTCH signaling by gamma secretase inhibitor engages the RB pathway and elicits cell cycle exit in T-cell acute lymphoblastic leukemia cells.

A. Look, J. O'neil, J. Hardwick, 2009, Cancer research.

FBW7 mutations in leukemic cells mediate NOTCH pathway activation and resistance to γ-secretase inhibitors

B. Clurman, R. Sears, R. Pieters, 2007, The Journal of experimental medicine.